Jeff Allen: I’ll be sharing results from our ctMoniTR Project.

Jeff Allen, President and CEO of Friends of Cancer Research, shared a post on LinkedIn:

“This week at the Society for Immunotherapy of Cancer (SITC) annual meeting preconference program I’ll be sharing results from our ctMoniTR Project.

We’ve aggregated data across multiple NSCLC clinical trials and show that in two different drug class cohorts – Step 1 (ICI Treated) and Step 2 (TKI Treated) – that changes in ctDNA levels may be an early indicator of treatment response and predict long-term outcomes.

ctMoniTR is a unique collaboration across government experts, leading academic researchers, patient advocates, drug developers, and diagnostic test developers. This research partnership aims to provide foundational evidence to help characterize the use of ctDNA as a molecular response measure to accelerate cancer research.
Thank you to all of our partners! More info on the ctMoniTR Project here. ”

Source: Jeff Allen/LinkedIn